MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

被引:119
|
作者
Gao, Lanlan [1 ,2 ]
Guo, Qianqian [1 ,2 ]
Li, Xiaoman [3 ]
Yang, Xuan [1 ,2 ]
Ni, Haiwei [1 ,2 ]
Wang, Ting [1 ,2 ]
Zhao, Qiong [1 ,2 ]
Liu, Hai [1 ,2 ]
Xing, Yingying [1 ,2 ]
Xi, Tao [1 ,2 ]
Zheng, Lufeng [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
[3] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China
来源
EBIOMEDICINE | 2019年 / 41卷
基金
中国博士后科学基金;
关键词
miR-873; PD-L1; Cancer stem cells; Drug resistance; PI3K/Akt; ERK1/2; PD-L1; EXPRESSION; TUMOR-SUPPRESSOR; IFN-GAMMA; TAMOXIFEN RESISTANCE; DRUG-RESISTANCE; TARGETING CDK3; B7-H1; METASTASIS; CHEMORESISTANCE; PROGRESSION;
D O I
10.1016/j.ebiom.2019.02.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Breast cancer stem cells have self-renewal capability and are resistant to conventional chemotherapy. PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells. However, the mechanisms by which PD-L1 regulates the stemness of breast cancer cells and PD-L1 is regulated in breast cancer cells are still unclear. Methods: Lentivirus infectionwas used to construct stable cell lines. The correlation between PD-L1 and stemness markers expression was evaluated in clinical samples. Additionally, luciferase reporter assay combined with RNA-Fluorescence in situ hybridization (RNA-FISH) and RNA-binding protein immunoprecipitation (RIP) assays were used to verify the direct binding of miR-873 on PD-L1. Furthermore, flowcytometry, mammosphere formation combined with nude mouse tumor xenograftmodel were carried out to examine the effects ofmiR-873/PDL1 axis on the stemness of breast cancer cells. Finally, MTT assay was performed to determine the effects of miR873/ PD-L1 axis on drug resistance. Findings: PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. Mechanistically, miR-873 inhibited PD-L1 expression through directly binding to its 3'-untranslated region (UTR), and miR-873 attenuated the stemness and chemoresistance of breast cancer cells which was dependent on PD-L1 and the downstream PI3K/Akt and ERK1/2 signaling. Notably, the promotion of PD-L1 on the stemness and chemoresistance was enhanced by recombinant PD-1 (rPD-1), this effect was attenuated by PD-1/PD-L1 inhibitor. Interpretation: miR-873/PD-L1 regulatory axis might serve as a therapeutic target to enhance the chemosensitivity and eliminate the stemness of breast cancer cells. Fund: This work was supported by the National Nature Science Foundation of China, No. 81702957, China Postdoctoral Science Foundation, No. 2017M620230, the Postdoctoral Research Funding Scheme of Jiangsu Province (2017), No. 1701197B, and the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. (c) 2019 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:395 / 407
页数:13
相关论文
共 50 条
  • [31] Differential expression of miR-873, miR-181a and miR-17-5p and their correlation with immune checkpoints PD-L1 and CD155 among hepatocellular carcinoma patients
    Eltahtawy, O.
    Gomaa, A.
    Youness, R. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1385 - S1386
  • [32] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [33] Circular RNA DGKB Promotes the Progression of Neuroblastoma by Targeting miR-873/GLI1 Axis
    Yang, Jiale
    Yu, Leitao
    Yan, Jinlong
    Xiao, Yu
    Li, Weiming
    Xiao, Juhua
    Lei, Jun
    Xiang, Deng
    Zhang, Shouhua
    Yu, Xin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] PD-1/PD-L1 axis in cancer cells contributes to cellular EMT in lung adenocarcinoma
    Su, Wen-Pin
    Chang, Li-Chan
    Yan, Jing-Jou
    Su, Wu-Chou
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
    Nakhjavani, Maryam
    Shigdar, Sarah
    PHARMACOLOGICAL RESEARCH, 2022, 175
  • [36] Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
    Yeni Romero
    Randi Wise
    Anna Zolkiewska
    Cancer Immunology, Immunotherapy, 2020, 69 : 43 - 55
  • [37] Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
    Romero, Yeni
    Wise, Randi
    Zolkiewska, Anna
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (01) : 43 - 55
  • [38] Increased PD-L1 expression in breast and colon cancer stem cells
    Wu, Yanheng
    Chen, Mingshui
    Wu, Peihong
    Chen, Chen
    Xu, Zhi Ping
    Gu, Wenyi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (05): : 602 - 604
  • [39] Expression of PD-L1 in lung cancer cells regulates Treg cell differentiation
    Shi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S59 - S59
  • [40] The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
    Yajuk, Olga
    Baron, Maya
    Toker, Sapir
    Zelter, Tamir
    Fainsod-Levi, Tanya
    Granot, Zvi
    CELLS, 2021, 10 (06)